[1]吴圆琴.甘精胰岛素联合阿卡波糖治疗2型糖尿病的效果及对胰岛素抵抗的影响[J].医学信息,2023,36(19):148-151.[doi:10.3969/j.issn.1006-1959.2023.19.033]
　WU Yuan-qin.Effect of Insulin Glargine Combined with Acarbose in the Treatment of Type 2 Diabetes Mellitus and its Effect on Insulin Resistance[J].Journal of Medical Information,2023,36(19):148-151.[doi:10.3969/j.issn.1006-1959.2023.19.033]
点击复制

甘精胰岛素联合阿卡波糖治疗2型糖尿病的效果及对胰岛素抵抗的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年19期
页码:
148-151
栏目:
药物与临床
出版日期:
2023-10-01

文章信息/Info

Title:
Effect of Insulin Glargine Combined with Acarbose in the Treatment of Type 2 Diabetes Mellitus and its Effect on Insulin Resistance
文章编号:
1006-1959（2023）19-0148-04
作者:
吴圆琴
（金溪县中医院药剂科，江西 金溪 344800）
Author(s):
WU Yuan-qin
(Department of Pharmacy,Jinxi County Hospital of Traditional Chinese Medicine,Jinxi 344800,Jiangxi,China)
关键词:
2型糖尿病; 甘精胰岛素; 阿卡波糖; 胰岛素抵抗; 低血糖
Keywords:
Type 2 diabetes mellitus; Insulin glargine; Acarbose; Insulin resistance; Hypoglycemia
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2023.19.033
文献标志码:
A
摘要:
目的 研究甘精胰岛素（IGlar）联合阿卡波糖治疗2型糖尿病（T2DM）的效果及对胰岛素抵抗的影响。方法 选取2019年12月-2021年12月金溪县中医院收治的62例T2DM患者，按照随机数字表法分为对照组（31例）与观察组（31例）。对照组给予普通胰岛素联合阿卡波糖治疗，观察组应用IGlar联合阿卡波糖治疗，比较两组降糖效果、血糖水平[糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2h血糖（2hPG）]、胰岛功能[胰岛素分泌指数（HOMA-β）、胰岛素抵抗指数（HOMA-IR）]、治疗相关指标（血糖达标时间、胰岛素每天用量、低血糖发生率）、不良反应发生率。结果 观察组降糖有效率高于对照组（P＜0.05）；观察组HbA1c、FPG、2hPBG水平低于对照组（P＜0.05）；观察组HOMA-β高于对照组，HOMA-IR低于对照组（P＜0.05）；观察组血糖达标时间、日均胰岛素用量、低血糖发生率均低于对照组（P＜0.05）；观察组不良反应发生率低于对照组（P＜0.05）。结论 IGlar联合阿卡波糖具有良好的降糖疗效，可有效降低T2DM患者的血糖水平，改善其胰岛功能，减少胰岛素抵抗，且降糖时间更短、胰岛素用量更少，不良反应发生风险更低。
Abstract:
Objective To study the effect of insulin glargine (IGlar) combined with acarbose in the treatment of type 2 diabetes mellitus (T2DM) and its influence on insulin resistance.Methods A total of 62 patients with T2 DM admitted to Jinxi County Hospital of Traditional Chinese Medicine from December 2019 to December 2021 were selected and divided into control group (31 patients) and observation group (31 patients) according to random number table method. The control group was treated with ordinary insulin combined with acarbose, and the observation group was treated with IGlar combined with acarbose. The hypoglycemic effect, blood glucose level [glycated hemoglobin (HbA1c), fasting blood glucose (FPG), 2 h postprandial blood glucose (2hPG)], islet function [insulin secretion index (HOMA-β), insulin resistance index (HOMA-IR)], treatment-related indicators (blood glucose compliance time, daily insulin dosage, incidence of hypoglycemia), and incidence of adverse reactions were compared between the two groups.Results The effective rate of hypoglycemic in the observation group was higher than that in the control group (P<0.05). The levels of HbA1 c, FPG and 2 hPBG in the observation group were lower than those in the control group (P<0.05). HOMA-β in the observation group was higher than that in the control group, and HOMA-IR was lower than that in the control group (P<0.05). The time of blood glucose reaching the standard, daily average insulin dosage and incidence of hypoglycemia in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).Conclusion IGlar combined with acarbose has a good hypoglycemic effect, which can effectively reduce the blood glucose level of T2DM patients, improve their islet function, reduce insulin resistance, and have shorter hypoglycemic time, less insulin dosage, and lower incidence of adverse reactions.

参考文献/References:

[1]李静静,方枝俏,奚超,等.阿卡波糖联合甘精胰岛素对2型糖尿病患者胰岛功能、血脂水平的影响及安全性[J].临床误诊误治,2022,35(4):36-39,45.[2]陈鹤鸣,张晓军,陈浩,等.阿卡波糖联合西格列汀对2型糖尿病患者糖脂代谢紊乱及慢性炎性反应的作用[J].疑难病杂志,2022,21(3):287-292.[3]甘明珠.甘精胰岛素联合阿卡波糖对绝经期糖尿病患者糖脂代谢、空腹C肽、血管内皮功能及炎症因子的影响[J].海军医学杂志,2020,41(5):552-556,560.[4]石玉英.甘精胰岛素联合阿卡波糖治疗2型糖尿病疗效观察[J].中国药物与临床,2020,20(11):1829-1830.[5]彭静,张文,栾家杰.阿卡波糖联合格列吡嗪治疗2型糖尿病临床疗效的系统评价[J].解放军医药杂志,2020,32(5):53-56.[6]王博,刘珺,张玄娥,等.阿卡波糖、沙格列汀联合甘精胰岛素对初发2型糖尿病患者血糖波动的影响[J].同济大学学报(医学版),2020,41(1):57-62.[7]高轩,胡倩,李洪林.阿卡波糖联合甘精胰岛素治疗2型糖尿病的临床效果及对患者氧化应激的影响[J].中国临床医生杂志,2020,48(4):424-426.[8]程雪梅,戚筠.甘精胰岛素联合GLP-1受体激动剂对2型糖尿病患者胰岛素功能及血糖的影响[J].药物生物技术,2020,27(2):127-130.[9]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.[10]李黎,盖雪松.西格列汀联合阿卡波糖对2型糖尿病患者胰岛β细胞功能及血清葡萄糖转运蛋白4水平影响[J].临床军医杂志,2019,47(4):417-418,421.[11]吕若琳,刘松,徐丽丽,等.钠-葡萄糖共转运体2抑制剂：超越降糖作用的心肾保护作用及对2型糖尿病患者骨代谢和骨折风险的影响[J].中华内分泌代谢杂志,2022,38(9):823-829.[12]戚仁娟,撒小军,宋洁,等.甘精胰岛素与阿卡波糖分别联合二甲双胍对2型糖尿病患者长期血糖控制对比分析[J].中国药物警戒,2018,15(12):709-712,727.[13]牛海涛.甘精胰岛素联合阿卡波糖对青年超重2型糖尿病患者胰岛功能的影响[J].中国临床医生杂志,2018,46(12):1443-1446.[14]Mccrimmon RJ,Sifri SA,Emral R,et al.Advancing therapy with iGlarLixi versus Premix 70/30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMixrandomised controlled trial[J].Diabetes Obesity and Metabolism,2021,23(6):1221-1231.[15]杨华,王述进,左红,等.二甲双胍联合阿卡波糖治疗新诊断2型糖尿病疗效观察[J].海南医学,2018,29(10):1442-1444.[16]庞静,李霞,徐杰,等.西格列汀联合阿卡波糖治疗Ⅱ型糖尿病对脂代谢紊乱与胰岛素抵抗的影响[J].西部医学,2017,29(10):1373-1376.[17]吴燕,邹晓华,阮荣耀,等.甘精胰岛素联合阿卡波糖治疗对糖尿病患者血清因子 抗氧化因子及胰岛β细胞的影响[J].中国药物与临床,2020,20(2):250-251.[18]徐倩.甘精胰岛素联合口服降糖药治疗2型糖尿病疗效分析[J].中国病案,2018,19(9):91-93.[19]刘媛.瑞格列奈联合甘精胰岛素对2型糖尿病患者胰岛β细胞功能及血清葡萄糖转运蛋白4的影响[J].中国医药导报,2017,14(6):81-84.[20]杨华,许学忠,祁平,等.甘精胰岛素注射液联合阿卡波糖片治疗继发性磺脲类药物失效的2型糖尿病的临床研究[J].中国临床药理学杂志,2017,33(3):219-221.[21]左丽娟,李明霞,邓文娟,等.甘精胰岛素联合诺和龙对2型糖尿病患者 胰岛功能及TNF-α,IL-6的影响[J].北华大学学报(自然科学版),2019,20(4):498-501.[22]刘燕霞.甘精胰岛素和阿卡波糖片用于老年糖尿病治疗中的临床效果[J].黑龙江医药,2019,32(1):101-102.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(19):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(19):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(19):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(19):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(19):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
　LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(19):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
　DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(19):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(19):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
　LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(19):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
　BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Journal of Medical Information,2018,31(19):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
[11]韩丽丽.甘精胰岛素与格列美脲联合治疗口服降糖药控制不佳 2型糖尿病的疗效[J].医学信息,2019,32(18):146.[doi:10.3969/j.issn.1006-1959.2019.18.050]
　HAN Lili.Therapeutic Effect of Insulin Glargine Combined with Glimepiride on Oral Hypoglycemic Agents for Poor Control of Type 2 Diabetes[J].Journal of Medical Information,2019,32(19):146.[doi:10.3969/j.issn.1006-1959.2019.18.050]
[12]尤 丽,卢 琦.甘精胰岛素联合二甲双胍治疗2型糖尿病的疗效[J].医学信息,2020,33(02):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
　YOU Li,LU Qi.Effect of Insulin Glargine Combined with Metformin in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2020,33(19):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
[13]单秋妹.德谷门冬双胰岛素与甘精胰岛素治疗口服降糖药控制不佳2型糖尿病的临床疗效[J].医学信息,2023,36(11):117.[doi:10.3969/j.issn.1006-1959.2023.11.023]
　SHAN Qiu-mei.Clinical Efficacy of Insulin Degludec and Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus with Poor Control of Oral Hypoglycemic Drugs[J].Journal of Medical Information,2023,36(19):117.[doi:10.3969/j.issn.1006-1959.2023.11.023]

更新日期/Last Update: 1900-01-01